Plant-made vaccine antigens and biopharmaceuticals

    Authors

    H. Daniell; N. D. Singh; H. Mason;S. J. Streatfield

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Trends Plant Sci.

    Keywords

    B SURFACE-ANTIGEN; TRANSGENIC TOBACCO PLANTS; HIGH-LEVEL EXPRESSION; VIRUS-LIKE PARTICLES; SYSTEMIC IMMUNE-RESPONSE; FIBROBLAST-GROWTH-FACTOR; HIGH-YIELD EXPRESSION; LACTUCA-SATIVA L.; HEPATITIS-B; ORAL IMMUNIZATION; Plant Sciences

    Abstract

    Plant cells are ideal bioreactors for the production and oral delivery of vaccines and biopharmaceuticals, eliminating the need for expensive fermentation, purification, cold storage, transportation and sterile delivery. Plant-made vaccines have been developed for two decades but none has advanced beyond Phase I. However, two plant-made biopharmaceuticals are now advancing through Phase II and Phase III human clinical trials. In this review, we evaluate the advantages and disadvantages of different plant expression systems (stable nuclear and chloroplast or transient viral) and their current limitations or challenges. We provide suggestions for advancing this valuable concept for clinical applications and conclude that greater research emphasis is needed on large-scale production, purification, functional characterization, oral delivery and preclinical evaluation.

    Journal Title

    Trends in Plant Science

    Volume

    14

    Issue/Number

    12

    Publication Date

    1-1-2009

    Document Type

    Review

    Language

    English

    First Page

    669

    Last Page

    679

    WOS Identifier

    WOS:000272855700005

    ISSN

    1360-1385

    Share

    COinS